Skip to content

Study · Not a test of the peptide alone · 2002

1 result

Effects of a non-IGF binding mutant of IGFBP-5 on cell death in human breast cancer cells.

Perks CM, McCaig C, Clarke JB, Clemmons DR, Holly JM

Biochemical and biophysical research communications1 Jun 2002Cited by 18 (Europe PMC)

PMID12074575 (opens in a new tab)DOI10.1016/s0006-291x(02)00570-3 (opens in a new tab)PepBankPUB-12074575
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 LR3.

  1. 01LabNot a test of IGF-1 LR3 aloneIn vitro (cells)Activity measurement

    In human breast cancer cells, long R3 IGF-I in the presence of wild type IGFBP-5 was unable to confer survival against ceramide-induced cell death.

    In plain wordsIn lab tests on breast cancer cells, long R3 IGF-I did not protect cells from death when wild type IGFBP-5 was present.

    Peptide
    IGF-1 LR3
    Outcome
    No significant changeCell survival with LR3 IGF-I and wild type IGFBP-5
    Study

    humann: not reported in source

    Human breast cancer cells (MCF-7)
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    in the presence of wild type IGFBP-5, long R3 IGF-I was also unable to confer survival.
    1 context sentence
    Summary · context
    To investigate if IGFBP-5 maintains its intrinsic ability to modulate apoptosis in IGF-responsive cells, we used a non-IGF binding mutant of IGFBP-5.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.